Geode Capital Management LLC Has $8.90 Million Stake in Cryoport, Inc. (NASDAQ:CYRX)

Geode Capital Management LLC increased its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX) by 3.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,097,369 shares of the company’s stock after acquiring an additional 38,520 shares during the quarter. Geode Capital Management LLC owned about 2.22% of Cryoport worth $8,902,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. AXA S.A. boosted its position in Cryoport by 274.2% during the second quarter. AXA S.A. now owns 873,217 shares of the company’s stock worth $6,034,000 after purchasing an additional 639,855 shares during the period. Federated Hermes Inc. bought a new stake in shares of Cryoport during the 2nd quarter worth about $774,000. Point72 Asset Management L.P. bought a new stake in shares of Cryoport during the 3rd quarter worth about $3,405,000. Bullseye Asset Management LLC grew its stake in Cryoport by 58.7% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock valued at $1,737,000 after buying an additional 79,244 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Cryoport in the 3rd quarter valued at about $105,000. Institutional investors own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CYRX shares. UBS Group boosted their price objective on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Roth Mkm reduced their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Finally, Guggenheim initiated coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Cryoport currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.29.

Cryoport Price Performance

Shares of NASDAQ CYRX opened at $7.78 on Thursday. The business has a fifty day moving average price of $7.49 and a two-hundred day moving average price of $7.85. The stock has a market capitalization of $384.57 million, a PE ratio of -2.30 and a beta of 1.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total transaction of $339,000.00. Following the transaction, the chief executive officer now owns 712,747 shares of the company’s stock, valued at approximately $4,832,424.66. This represents a 6.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock valued at $735,673 over the last quarter. 10.10% of the stock is owned by corporate insiders.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.